Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well lapatinib works in treating patients with recurrent
or persistent endometrial cancer. Lapatinib may stop the growth of tumor cells by blocking
the enzymes necessary for their growth